39 results about "Cell recruitment" patented technology

A method is provided for facilitating treatment of a patient, including stressing a portion of the patient to an extent sufficient to induce homing of progenitor cells to the portion of the patient. A method is additionally provided for use with tissue of a patient, including evaluating an indication of a level of stromal cell-derived factor-1 (SDF-1) in the tissue, and determining an indication of a number of stem cells in the tissue responsive to the indication of the level of SDF-1. A method is yet additionally provided for use with tissue of a patient, including evaluating an indication of a level of SDF-1 in the tissue, and determining an indication of a level of stress of a portion of the patient, responsive to the indication of the level of SDF-1. Other embodiments are also described.

Method and apparatus are disclosed for treating congestive heart failure. The method includes relieving wall stress on a diseased heart by an amount to decrease a rate of myocardial cell loss. Further, the method includes pharmacologically encouraging a myocardial cell gain. Cell gain may be encouraged by cell replication, cell recruitment or inhibition of cell death. Further embodiments of the method include a passive cardiac constraint selected to reduce wall stress on the heart. An apparatus of the present invention includes a passive cardiac constraint and a pharmacological agent to encourage cell gain.

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

The invention is directed to methods of inducing cell recruitment and tissue regeneration at a target site in a subject. It is also based, in part, on the discovery that a subject's own biologic resources and environmental conditions can be used for in situ tissue regeneration and thereby reduce or eliminate the need for donor cell procurement and ex vivo manipulation of such donor cells. Methods are disclosed for recruitment of a subject's own stem cells to a target region by inducing a sustained positive pressure at a target site, such as the kidney, thereby increasing the number of pluripotent cells capable of differentiating to regenerate the target tissue.

Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.

Methods and apparatus are disclosed for treating congestive heart failure. The method includes relieving wall stress on a diseased heart by an amount to decrease a rate of myocardial cell loss. Further, the method includes pharmacologically encouraging a myocardial cell gain. Cell gain may be encouraged by cell replication, cell recruitment or inhibition of cell death. Further embodiments of the method include a passive cardiac constraint selected to reduce wall stress on the heart. An apparatus of the present invention includes a passive cardiac constraint and a pharmacological agent to encourage cell gain.

The present invention relates to the use of matrices in cell recruitment and the to modified matrices comprising homing factors for in vivo recellularisation of implantable medical devices such as cardiac valves and vascular grafts.

A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen.

The invention relates to a human immunity improving traditional Chinese medicine preparation and a preparation method. The method includes: a, preparing culture medium mixed solution; b, sterilizing;c, cooling, d, performing inoculation to obtain fermented liquid; c, performing standing treatment to obtain the human immunity improving traditional Chinese medicine preparation. The human immunity improving traditional Chinese medicine preparation is capable of improving an in-vivo micro-ecological environment, balancing and regulating intestinal probiotics, repairing damaged cells, replenishingvarious in-vivo active bio-enzymes, amino acids, nucleic acids, trace elements and the like, improving human immunity and preventing diseases. In addition, the human immunity improving traditional Chinese medicine preparation is capable of improving acidic physique into alkalescent physique, can be used for preparing pills, ointments, aqueous solutions and the like and has a great auxiliary treatment effect in human immunity improvement.

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen is B7H3.

The invention discloses an erythrocyte gel delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological materials. The preparation method comprises the following steps: uniformly mixing an active ingredient or a delivery carrier containing the active ingredient and fresh blood, and performing mild drying after preliminary coagulation toprepare the erythrocyte gel delivery system. The preparation method of the erythrocyte gel delivery system provided by the invention is simple and fast, and the erythrocyte gel delivery system has theadvantages of high drug loading, high biological safety and high biodegradability; erythrocyte gel has the effects of immune stimulation and immune cell recruitment, and can form an immune niche at an implantation site; an immunomodulator and a tumor-associated antigen contained in the erythrocyte gel vaccine prepared by the method stimulates recruited immune cells to differentiate into immune cells with tumor antigen specificity after being implanted, and induce production of highly effective anti-tumor immune responses.

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and / or activation. The method comprises administering to a subject in need an effective amount of a compound represented by structural formula (I) or physiologically acceptable salt thereof.

The invention relates to a fiber wound repair stent loaded with phase change material particles as well as a preparation method and application of the fiber wound repair stent. According to the invention, aliphatic polyester, a natural polymer and a phase change material are used as main raw materials, antibacterial drugs, active substance particles and growth factors are added, and the multi-layer scaffold with biological activity is prepared through electrostatic spinning, electrostatic spraying and the like. Different types of antibacterial drugs are added into the fiber wound repair stent provided by the invention, so that multiple antibacterial effects are achieved; the bioactive substance particles with the deposition density gradient increased are contained, so that cell recruitment and migration are promoted; the phase-change material particles containing the repair-promoting growth factors are used for regulating and controlling behaviors of different cells through photo-thermal trigger type controllable delivery of the growth factors. The stent material provided by the invention has excellent biocompatibility and degradation performance, can mediate migration, proliferation, differentiation and paracrine effects of cells, and can accelerate the wound repair speed and improve the wound healing effect.

The invention relates to an injectable bone induction repair material and a preparation method thereof, and belongs to the technical field of biomedical materials. The preparation method specifically comprises the following steps of: S1, performing mineralization treatment on biological bones to obtain mineral substances from the biological bones, and crushing the mineral substances from the biological bones to obtain composite inorganic mineralized particles; S2, performing oscillation adsorption on active factors and the composite inorganic mineralized particles, so that the active factors are stably adsorbed on the surfaces of the composite inorganic mineralized particles through electrostatic attraction to obtain adsorbed composite inorganic mineralized particles; and S3, uniformly mixing the adsorbed composite inorganic mineralized particles with a gel aqueous solution to obtain the bone induction repair material. The bone induction repair material prepared by the preparation method is easy to shape and can be used through injection; and the bone induction repair material has ultrahigh crystallinity and crystallization purity, and pores are communicated with each other, so that cells can be combined with the active factors to promote cell recruitment.

The invention herein is related to the use of Lactobacillus reuteri strains as immune enhancing agents, methods of improving immune-function in mammals using Lactobacillus reuteri strains in products containing cells of such strains and the products as such. These strains exhibit good toxin binding and neutralizing effect, and exhibit good CD4+ cell recruitment.

The present invention relates, in part, to bispecific chimeric proteins that find use in various immunotherapies based on various properties, including, for example, a dual immune cell recruitment andimmune signal delivery function.

The instant invention is based, at least in part, on the discovery that T-bet controls ThI cell recruitment to sites of inflammation. This invention pertains to, inter alia, methods of identifying agents that modulate the effects of T-bet on the recruitment of T cells to sites of inflammation by modulating P-selectin-mediated T cell rolling and / or stable adherence of a T cell to a vascular endothelial cell, as well as methods of use therefore.

Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem and progenitor cells. It is a devastating disease with a poor prognosis and an average 5-year survival rate of about 30%. Disclosed herein are composition and methods for treating leukemia with a biomaterial comprising a polymer scaffold, a dendritic cell activating factor, a dendritic cell recruitment factor, and at least one leukemia antigen. The biomaterial-based vaccine disclosed herein promotes a potent, durable and transferable immune response against acute myeloid leukemia to prevent cell engraftment and synergizes with chemotherapy to prevent relapse.

Inflammation is a prominent feature of ischemia-reperfusion injury (IRI) characterized by leukocyte infiltration and renal tubular injury. However, the signals that initiate these events remain poorly understood. The inventors identify the nuclear alarmin interleukin (IL)-33 as an initiation factor of tissue injury and also as a major amplification factor of the innate immune response triggered by experimental kidney ischemia-reperfusion in mice. In mice lacking IL-33, IRI is reduced, as attested by early decreased tubular cell injury, and by subsequent decreased infiltration of IFN-γ / IL-17A-producing neutrophils and preservation of renal functions. These findings led the inventors to propose that endogenous IFN-33 contributes to kidney IRI by promoting iNKT cell recruitment and cytokine production, resulting in neutrophil infiltration and activation at the injury site. Accordingly, the present invention relates to antagonists of IL-33 for use in methods for preventing ischemia reperfusion injury in an organ.

It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.

The invention discloses a bispecific antibody for multiple myeloma and its application, and belongs to the technical field of genetic engineering antibodies. In the present invention, the antibody F00 targeting human BCMA and the antibody D00 targeting human PD-1 are used as parent antibodies, and 'knob' and 'hole' ends are respectively introduced into the two heavy chain Fc according to the CrossMab platform using genetic engineering technology. Animal eukaryotic expression system expresses DF00. The present invention also provides a method for expressing and purifying the bispecific antibody DF00. The target protein is obtained by secreting expression of HEK293 cells and purifying by affinity chromatography. The bispecific antibody DF00 can specifically bind to both the BCMA molecule on the surface of multiple myeloma (MM) cells and the immune checkpoint molecule PD-1 on the surface of activated T cells, inhibiting the immunosuppressive microenvironment in tumors and promoting T cells Recruited to surrounding multiple myeloma cells, remodeling the function of T cells to kill MM cells.

The invention is directed to methods of inducing cell recruitment and tissue regeneration at a target site in a subject. It is also based, in part, on the discovery that a subject's own biologic resources and environmental conditions can be used for in situ tissue regeneration and thereby reduce or eliminate the need for donor cell procurement and ex vivo manipulation of such donor cells. Methods are disclosed for recruitment of a subject's own stem cells to a target region by inducing a sustained positive pressure at a target site, such as the kidney, thereby increasing the number of pluripotent cells capable of differentiating to regenerate the target tissue.

The invention discloses a bispecific antibody for multiple myeloma (MM) and application of the bispecific antibody, and belongs to the technical field of genetic engineering antibodies. An antibody F00 targeting human BCMA and an antibody D00 targeting human PD-1 are used as parent antibodies, a 'knob' end and a 'hole' end are respectively introduced to two heavy chains Fc by a gene engineering technology according to a CrossMab platform, and a mammal eukaryotic expression system expresses DF00. The invention further provides a method for expressing and purifying the bispecific antibody DF00.A target protein is obtained through HEK293 cell secretory expression and affinity chromatography purification. The bispecific antibody DF00 can specifically bind to a BCMA molecule on the surface ofMM cells and an immune checkpoint molecule PD-1 on the surface of activated T cells at the same time, inhibit an immunosuppressive microenvironment in tumors and recruit T cells around the MM cells toremodel the MM cell killing function of the T cells.

The invention relates to the field of tissue regeneration biological material development, and discloses a gel microcapsule which carries a stroma cell-derived factor-1 alpha nanoparticles and a platelet-derived growth factor-BB nanoparticles and has a cell recruitment function and a preparation method thereof, and a gel microcapsule preparation with the cell recruitment function and a preparation method thereof. The gel microcapsule with the cell recruitment function and the preparation thereof can be applied to the dentistry to promote regeneration of endogenous periodontium by recruiting own stem cells of the organism. The gel microcapsule with the cell recruitment function is characterized by comprising the stroma cell-derived factor-1 alpha nanoparticles and the platelet-derived growth factor-BB nanoparticles, glycidyl methacrylate dextranum having the weight-average molecular weight of 100-105 kDa, gelatin having the weight-average molecular weight of 100 kDa, polypropylacrylamide having the weight-average molecular weight of 17 kDa, and a cosolvent, an emulsifier and a stabilizer.

The present invention relates to a conditionally bispecific redirected activation construct or COBRA administered in the form of an active prodrug. Upon exposure to a tumor protease, the constructs are cleaved and activated such that they are able to bind both tumor target antigens (TTAs) and CD3, thereby recruiting CD3-expressing T cells to the tumor for treatment. In some embodiments, the tumor target antigen is B7H3.

The present invention discloses a method for isolating bioactive peptides and / or binding domains in an inactive ("off") state until binding to a second designed polypeptide, referred to as a key, only when a protein switch component is co-localized when bound to its target. The polypeptides induce protein switches that activate ("open") the conformational change of the bioactive peptide or binding domain, components of such protein switches, and uses thereof.

The present invention relates to a fibrous wound repair scaffold loaded with phase change material particles, and a preparation method and application thereof. The invention uses aliphatic polyester, natural macromolecules and phase change materials as main raw materials, adds antibacterial drugs, active substance particles and growth factors, and prepares a multi-layered scaffold with biological activity through electrospinning, electrostatic spraying and the like. The fiber wound repair scaffold provided by the invention adds different kinds of antibacterial drugs to achieve multiple antibacterial effects; contains biologically active substance particles with increased deposition density gradient to promote cell recruitment and migration; contains phase change material particles that promote repair growth factors, To modulate the behavior of different cells by photothermally-triggered controllable delivery of growth factors. The scaffold material provided by the invention has excellent biocompatibility and degradability, can mediate cell migration, proliferation, differentiation and paracrine effect, and can speed up wound repair and improve wound healing effect.

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and / or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof